OBJECTIVES: Nausea and Vomiting of Pregnancy (NVP) is the most common condition, which affecting up to 80% of all pregnant women to some degree. Serious form of NVP (hyperemesis gravidarum) affects less than 1% of women, but it can be requiring hospitalization and rehydration. Severe NVP have a high prevalence (80% worldwide) and reduce the quality of life, productivity, develop depression.In Ukraine the statistic data about number of NVP are not currently conducted. METHODS: Data analysis about effectiveness of drugs for the prevention and treatment of NVP. Sources of information were databases Cochrane, PubMed and publications in Ukrainian medical journals. RESULTS: Currently MoH doesn’t collects official statistics on the NVP. Also the medical protocol for NVP treatment in pregnant women is not approved. The analysis showed that some medicines are not registered in Ukraine, that are included in the European recommendations for the NVP treatment. For the treatment of NVP a combination of antihistamines and vitamin B6 often used, but these drugs are absent in Ukraine. In Ukrainian market  is registered only one dietary supplement that contains a combination of Gingeng extract and vitamin B6. We analyzed the costs for treatment of NVP per one week by antiemetic drugs from different producers. In Ukraine the costs for NVP treatment range from 8249,0 UAH (293 EUR) to 149,1 UAH (5290 EUR) per 100 woman/week (1 EUR = 28,20 UAH on 01.06.2016). At present, these costs are financed out of pocket by patient, having a significant impact on quality of life and outcomes. CONCLUSIONS: We have established that it is necessary to introduce the official statistics of NVP, especially with hyperemesis gravidarum in pregnant. We determined that combined drugs for the NVP treatment are necessary for market access. Also the state should finance these medications for pregnant women to improve their quality of life and reducing the cost of hospitalization.